The stock rose to Rs 368 apiece on the NSE, extending its rally for the fourth consecutive session. Cupid shares have gained more than 16% in a week, 30% in a month and 246% so far in 2026. The stock has surged 657% over the past year despite broader market weakness.
Also read | Cupid raises FY27 revenue, profit guidance again
Cupid FY27 outlook
Earlier this month, the condom-maker announced the second increase in profit and revenue guidance in less than two weeks, with the company now expecting to post a revenue of Rs 800 crore and net profit of Rs 250 crore in the ongoing financial year 2027.
Cupid continues to witness strong business momentum in FY27, with Q2 FY27 total revenue expected to cross Rs 200 crore. It added that the FY27 guidance was raised due to sustained momentum across its key business verticals and improved visibility across domestic and international markets.
The FY27 outlook has been revised upward, supported by strong Q2 FY27 business momentum expected to continue and grow through Q3 and Q4 FY27, improved visibility across institutional and private markets, continued expansion of the domestic FMCG business, progress towards imminent operationalisation of the Palava facility, and sustained growth across the Company’s healthcare, and personal care portfolio, Cupid said.
What Cupid expects now
Looking ahead, Cupid expects to scale domestic FMCG distribution to deepen Cupid’s presence across modern trade, general trade and pharmacy channels. It also plans to operationalise its Palava manufacturing facility to enhance production capacity, flexibility and supply capabilities across domestic and international markets. Expansion of healthcare and personal care portfolio through new products, regulatory approvals and wider commercialisation opportunities are also on the cards.Cupid also aims to strengthen its international healthcare business by expanding institutional, government and private-market opportunities across geographies, as well as build regional manufacturing platforms through the proposed South African venture, creating a potential base for wider international market expansion. It also plans to explore strategic healthcare opportunities through partnerships and investments that complement Cupid’s healthcare and personal care ecosystem.
The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits.
Also read | Why is market rising today?
Disclaimer: This article has been written by Debaroti Adhikary, who is not a SEBI-registered Research Analyst or an Investment Adviser. Debaroti Adhikary and his/her ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.
